<< Back To Search

A Study of TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myeloma

Notify the Multiple Myeloma Research Foundation You Are Interested In This Trial


Third Opinion Trial Synopsis:
This study wants to see if TTI-622 and daratumumab hyaluronidase-fihj are safe for people with multiple myeloma. They are looking for the best amount of TTI-622 that doesn't have many side effects when combined with daratumumab hyaluronidase-fihj. If they find a safe dose, they will test it on more people to see if it helps treat multiple myeloma. The researchers think combining TTI-621 or TTI-622 with daratumumab hyaluronidase-fihj could be a good way to treat this disease.
*Third Opinion AI Generated Synopsis

Trial Summary
This study will test the safety of TTI-622 in combination with daratumumab hyaluronidase-fihj in people with relapsed/refractory multiple myeloma. The researchers look for the highest dose TTI-622 that causes few or mild side effects in participants when given in combination with daratumumab hyaluronidase-fihj. Once the researchers find the highest safe dose of each study drug, they will further test the combination TTI-622 + daratumumab hyaluronidase-fihj) in new participants to find out if the combinations are effective in treating relapsed/refractory multiple myeloma. Researchers think that combining TTI-621 or TTI-622 with daratumumab hyaluronidase-fihj, a standard treatment for multiple myeloma, may be an effective treatment approach.

Locations & Contact

Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.

Please share any additional considerations or concerns:
Example: Are you newly diagnosed? What treatments have you already been on?